Translational Biomedicine is pleased to announce Special issue on “Translational approach to studies coronavirus”
As the virus has spread across over 180 countries, comparative analysis of SARS-CoV-2 genome will determine the mutation rate as well as help understand the transmission. Current measures are preventive, therefore studying host-pathogen interactions will be crucial towards advanced molecular diagnostics, the development of new therapies or repurposing of existing drugs and targeted drug delivery. Wider in-silico approaches will also help identify novel targets or drug candidates for testing. In addition, current advances in biotechnology are crucial to treat certain patients who may be at risk due to genetic susceptibility or underlying health conditions.
The clinical diagnosis of COVID-19, as well as the study of molecular mechanisms and pathology of the disease in different populations. It will expand to cover the study of the SARS-CoV-2 virus, using the latest genome editing technologies and computational methods. This collection proposes to encompass translational approaches in COVID-19 pathology, diagnostics, therapeutic target identification and drug development towards patient treatment.
Special issue articles can include both original unpublished research articles and review articles related to the specific theme
Manuscripts will be accepted for publishing in the special issue only after getting approved by the peer review committee.
All the articles in special issues should strictly adhere to journal style and formatting.
Each special issue can be created with 5-7 articles.
All accepted manuscripts can be submitted online via https://www.imedpub.com/submissions/translational-biomedicine.html or through an email id to [email protected]
Submission should be accompanied by a cover letter with reference to the concerned special issue theme.
Please visit Instruction for authors page to know more about article formatting and guidelines: https://www.transbiomedicine.com/author-guidelines.php